{"commentary":{"count":37,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":22,"podcast":11,"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT00433589\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MINDACT","nct_id":"NCT00433589","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mindact-nct00433589. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"MINDACT","arms":[{"description":"* FEC 100\n* Canadian CEF\n* CAF\n* FAC\n* E-CMF","label":"Chemotherapy randomization: Arm I (anthracycline-based)","type":"ACTIVE_COMPARATOR"},{"description":"* Docetaxel\n* Capecitabine","label":"Chemotherapy randomization: Arm II (docetaxel and capecitabine)","type":"EXPERIMENTAL"},{"description":"2 years of tamoxifen followed by 5 years of letrozole","label":"Endocrine therapy randomization: Arm I","type":"ACTIVE_COMPARATOR"},{"description":"7 years of letrozole","label":"Endocrine therapy randomization: Arm II","type":"EXPERIMENTAL"},{"description":"chemotherapy-decision-making according to clinical criteria (using Adjuvant! Online)","label":"Treatment decision randomization: Arm I","type":"ACTIVE_COMPARATOR"},{"description":"chemotherapy-decision-making according to genomic prognosis using the 70-gene signature","label":"Treatment decision randomization: Arm II","type":"EXPERIMENTAL"}],"collaborators":["Agendia","Breast International Group","Roche Pharma AG","Novartis","Sanofi"],"completion_date":{"date":"2020-03","type":"ACTUAL"},"conditions":["Breast Cancer"],"enrollment":{"count":6600,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"anthracycline-based","type":"DRUG"},{"name":"docetaxel and capecitabine","type":"DRUG"},{"name":"tamoxifen","type":"DRUG"},{"name":"Letrozole","type":"DRUG"}],"last_update":"2022-11-17","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","official_title":"MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy): A Prospective, Randomized Study Comparing the 70-Gene Signature With the Common Clinical-Pathological Criteria in Selecting Patients for Adjuvant Chemotherapy in Breast Cancer With 0 to 3 Positive Nodes","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2020-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Distant metastasis-free survival at 5 years","timeFrame":"from enrollment/randomization"},{"measure":"Disease-free survival (DFS)","timeFrame":"from enrollment/randomization"},{"measure":"DFS","timeFrame":"from enrollment/randomization"}],"references":[{"citation":"Mook S, Bonnefoi H, Pruneri G, Larsimont D, Jaskiewicz J, Sabadell MD, MacGrogan G, Van't Veer LJ, Cardoso F, Rutgers EJ. Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. Eur J Cancer. 2009 May;45(7):1201-1208. doi: 10.1016/j.ejca.2009.01.004. Epub 2009 Feb 14.","pmid":"19232484","type":"BACKGROUND"},{"citation":"Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol. 2008 Feb 10;26(5):729-35. doi: 10.1200/JCO.2007.14.3222.","pmid":"18258980","type":"BACKGROUND"},{"citation":"Cardoso F, Piccart-Gebhart M, Van't Veer L, Rutgers E; TRANSBIG Consortium. The MINDACT trial: the first prospective clinical validation of a genomic tool. Mol Oncol. 2007 Dec;1(3):246-51. doi: 10.1016/j.molonc.2007.10.004. Epub 2007 Oct 22.","pmid":"19383299","type":"BACKGROUND"},{"citation":"Mook S, Van't Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Cardoso F. Individualization of therapy using Mammaprint: from development to the MINDACT Trial. Cancer Genomics Proteomics. 2007 May-Jun;4(3):147-55.","pmid":"17878518","type":"BACKGROUND"},{"citation":"Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M; TRANSBIG consortium. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol. 2006 Oct;3(10):540-51. doi: 10.1038/ncponc0591.","pmid":"17019432","type":"BACKGROUND"},{"citation":"Viale G, Slaets L, Bogaerts J, Rutgers E, Van't Veer L, Piccart-Gebhart MJ, de Snoo FA, Stork-Sloots L, Russo L, Dell'Orto P, van den Akker J, Glas A, Cardoso F; TRANSBIG Consortium & the MINDACT Investigators. High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. Ann Oncol. 2014 Apr;25(4):816-823. doi: 10.1093/annonc/mdu026.","pmid":"24667714","type":"RESULT"},{"citation":"Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso F. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer. 2011 Dec;47(18):2742-9. doi: 10.1016/j.ejca.2011.09.016. Epub 2011 Nov 1.","pmid":"22051734","type":"RESULT"},{"citation":"Alaeikhanehshir S, Ajayi T, Duijnhoven FH, Poncet C, Olaniran RO, Lips EH, van 't Veer LJ, Delaloge S, Rubio IT, Thompson AM, Cardoso F, Piccart M, Rutgers EJT. Locoregional Breast Cancer Recurrence in the European Organisation for Research and Treatment of Cancer 10041/BIG 03-04 MINDACT Trial: Analysis of Risk Factors Including the 70-Gene Signature. J Clin Oncol. 2024 Apr 1;42(10):1124-1134. doi: 10.1200/JCO.22.02690. Epub 2024 Jan 19.","pmid":"38241603","type":"DERIVED"},{"citation":"Piccart M, van 't Veer LJ, Poncet C, Lopes Cardozo JMN, Delaloge S, Pierga JY, Vuylsteke P, Brain E, Vrijaldenhoven S, Neijenhuis PA, Causeret S, Smilde TJ, Viale G, Glas AM, Delorenzi M, Sotiriou C, Rubio IT, Kummel S, Zoppoli G, Thompson AM, Matos E, Zaman K, Hilbers F, Fumagalli D, Ravdin P, Knox S, Tryfonidis K, Peric A, Meulemans B, Bogaerts J, Cardoso F, Rutgers EJT. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 2021 Apr;22(4):476-488. doi: 10.1016/S1470-2045(21)00007-3. Epub 2021 Mar 12.","pmid":"33721561","type":"DERIVED"},{"citation":"Delaloge S, Piccart M, Rutgers E, Litiere S, van 't Veer LJ, van den Berkmortel F, Brain E, Dudek-Peric A, Gil-Gil M, Gomez P, Hilbers FS, Khalil Z, Knox S, Kuemmel S, Kunz G, Lesur A, Pierga JY, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Thompson AM, Viale G, Zoppoli G, Vuylsteke P, Tryfonidis K, Poncet C, Bogaerts J, Cardoso F; MINDACT investigators and the TRANSBIG Consortium. Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. J Clin Oncol. 2020 Apr 10;38(11):1186-1197. doi: 10.1200/JCO.19.01371. Epub 2020 Feb 21.","pmid":"32083990","type":"DERIVED"},{"citation":"Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.","pmid":"27557300","type":"DERIVED"}],"start_date":{"date":"2007-02"},"study_type":"INTERVENTIONAL","title":"Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes","url":"https://clinicaltrials.gov/study/NCT00433589"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mindact-nct00433589"}